$392 Million is the total value of Omega Fund Management, LLC's 15 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 46.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GOSS | Gossamer Bio | $154,227,000 | +2.4% | 6,953,416 | 0.0% | 39.34% | +23.5% | |
| REPL | Sell | Replimune Group | $74,567,000 | -51.8% | 5,103,455 | -50.0% | 19.02% | -41.9% |
| MORF | New | Morphic Holding | $58,857,000 | – | 2,969,582 | +100.0% | 15.01% | – |
| TBIO | Sell | Translate Bio | $30,787,000 | -38.0% | 2,437,603 | -50.0% | 7.85% | -25.2% |
| IMUX | New | Immunic | $15,731,000 | – | 1,371,494 | +100.0% | 4.01% | – |
| OBSV | Sell | ObsEva | $11,303,000 | -55.8% | 999,364 | -50.0% | 2.88% | -46.7% |
| PRTK | Sell | Paratek Pharmaceuticals | $10,376,000 | -62.8% | 2,600,410 | -50.0% | 2.65% | -55.1% |
| TRVI | New | Trevi Therapeutics | $9,476,000 | – | 1,263,408 | +100.0% | 2.42% | – |
| PRVL | New | Prevail Therapeutics | $8,830,000 | – | 668,908 | +100.0% | 2.25% | – |
| FGEN | Sell | FibroGen | $5,903,000 | -58.4% | 130,646 | -50.0% | 1.51% | -49.8% |
| PIRS | Sell | Pieris Pharmaceuticals | $3,546,000 | -32.0% | 754,457 | -51.5% | 0.90% | -18.0% |
| EPIX | Sell | ESSA Pharma | $2,658,000 | -64.1% | 1,084,848 | -50.0% | 0.68% | -56.6% |
| JNCE | Sell | Jounce Therapeutics | $2,623,000 | -60.1% | 529,965 | -50.0% | 0.67% | -51.8% |
| CDTX | Sell | Cidara Therapeutics | $2,535,000 | -68.3% | 1,508,794 | -50.0% | 0.65% | -61.7% |
| SNNAQ | Sell | Sienna Biopharmaceuticals | $660,000 | -81.2% | 758,610 | -50.0% | 0.17% | -77.4% |
| DRNA | Exit | Dicerna Pharmaceuticals | $0 | – | -334,314 | -100.0% | -1.04% | – |
| CBAY | Exit | CymaBay Therapeutics | $0 | – | -1,102,954 | -100.0% | -3.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.